https://d2f0ora2gkri0g.cloudfront.net/bkpam2127053_2a77e4d45fd3430f9b7e99239ba49fc0

Board & Key Advisors

Lokon Pharma is a wholly owned subsidiary of nxt2b, a leading venture capital company in Sweden that focuses on growth equity investments in healthcare, medical devices and specialty pharmaceutical companies. The board and key advisors include:

gallery/low-191002-1_132

Angelica Loskog, Ph.D.

CEO, Board of Directors

 

Angelica is a scientific advisor for the venture capital company nxt2b, Professor (adjunct) at Uppsala University, and Lokon Pharma’s CEO. She has over 20 years of experience in the immunotherapy field from research at Uppsala University and the Baylor College of Medicine. She performed the first clinical trial outside of the US using CD19-targeting CAR T-cells as well as clinical trials using AdCD40L immunotherapy. Angelica is also a board member of Vivolux, Bioimics, and RePos Pharma, as well as a former board member of Hansa Biopharma AB (Publ).

gallery/low-191002-1_165

Erika Kjellberg Eriksson, BSc.

Chairman of the Board

 

Erika holds a BSc. in Business Administration and Economy from Uppsala University. With over 15 years of experience in the life sciences sector, she is the CEO and chairman of the venture capital company nxt2b. She serves as Chairman/board member for many of the companies within the nxt2b corporate group. Before joining nxt2b, she was CFO at OxThera, VP and CFO at Q-Med, as well as CFO and CEO at BioPhausia.

gallery/low-191002-1_20

Kristin Ermanbriks

Board of Directors

 

Kristin is project coordinator at the venture capital company nxt2b. Kristin has previous experience working as Manager of Corporate Administration at Q-Med, Executive Assistant within Conpharm and Uppsala University, and Marketing Assistant at Pharmacia International.

gallery/low-191002-1_81

Eric Rowinsky, M.D.

Clinical Strategies Advisor/Chief Medical Officer

 

Eric has extensive experience and expertise in the development and registration of anti-cancer therapeutics. He is Executive Director and President of RGenix, CSO of Clearpath Development Co., and serves on the Board of Directors at Biogen. During the past years, he has also served as Director of BIND, Navidea and Fortress Biosciences, all of which are public life science companies. Previous positions include Stemline Therapeutics (Head of R&D, CMO, Executive VP), Primrose Therapeutics (co-founder, CEO), ImClone Systems, Inc. (CMO, Executive VP Clin Dev & Reg Affairs), and Director at Biogen. Previously, Eric was a Professor of Medicine at New York University and Assoc. Professor of Oncology at John Hopkins University School of Medicine.

gallery/malcolm brenner 2

Malcolm K. Brenner, M.D./Ph.D.

Scientific and Medical Advisor

 

Malcolm received his degrees from the University of Cambridge and is the Founding Director of the Center for Cell and Gene Therapy at Baylor College of Medicine (BCM). He serves as a Professor in the Departments of Pediatrics and of Medicine at BCM. He is a pioneer in the field of gene and cell therapy and has been the recipient of many awards including the ASGCT Outstanding Achievement Award and the American Society of Hematology Mentor Award.

gallery/bengt ågerup

Bengt Ågerup, Ph.D.

Scientific Advisor

 

Bengt received his degree from Uppsala University and is the founder of the venture capital company nxt2b. He has held senior positions within Pharmacia and Biomatrix as well as founding Q-Med, a world-leading company for dermal injectable fillers such as Restylane (sold to Galderma in 2011). Bengt is a former board member of the Swedish Foundation for Strategic Research and the former Chairman of Stockholm Uppsala Life Science.